September 17, 2024

Alkeus Pharmaceuticals Announces Results from the SAGA Study of Oral Gildeuretinol in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration

CAMBRIDGE, Mass., – Alkeus Pharmaceuticals, Inc. today announced that the SAGA study of oral gildeuretinol acetate (ALK-001) in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) demonstrated a reduction of 0.25 sqmm/year vs. placebo (p=0.07) in the primary endpoint of GA lesion growth rate at 24 months. Gildeuretinol demonstrated a statistically significant reduction in the loss of low luminance visual acuity (LLVA) at 24 months (p=0.03). Gildeuretinol showed a favorable safety profile consistent with other studies of gildeuretinol in Stargardt disease. The topline results will be presented as a late breaker at the 128th Annual Meeting of the American Academy of Ophthalmology (AAO) during Retina Subspecialty Day on Friday, October 18, in Chicago.

Learn More
July 18, 2024

Alkeus Pharmaceuticals Announces Presentation of a TEASE-3 Study Update Showing Progression Stalled in Early-Stage Stargardt Disease Patients Treated with Gildeuretinol

CAMBRIDGE, Mass. – Alkeus Pharmaceuticals, Inc. today announced the presentation of interim data from its TEASE-3 study demonstrating that early-stage Stargardt disease patients treated with gildeuretinol acetate showed no disease progression and remained asymptomatic while on therapy ranging between two and six years. The study update was presented during the 42nd American Society of Retina Specialists (ASRS) Annual Scientific Meeting, being held July 17-20 in Stockholm, Sweden.

Learn More
July 2, 2024

Accomplished Biotech Leader Michel Dahan Joins Alkeus as President and CEO

CAMBRIDGE, Mass. – Alkeus Pharmaceuticals, Inc. announced today that Michel Dahan has joined the company as President and Chief Executive Officer and will be responsible for leading the organization’s growth in preparation for commercial launch of its lead asset, gildeuretinol acetate, as a potential treatment for Stargardt disease. Alkeus Co-Founder Leonide Saad, Ph.D., has been named Chief Scientific Officer and will remain an integral part of the company’s continued development of novel treatments for serious diseases of the eye.

Learn More